Chapter 441: Nova's crisis

"David, how is the development progress of ranibizumab?" An executive at Nova's headquarters learned from other executives about the progress of new drug development. Ranibizumab is the new drug they developed for macular degeneration. It is also a key project of Nova Corporation in recent years. According to their judgment on the market, once approved by the FDA, this will be a blockbuster drug.
"Steve, the clinical trial is very smooth. It is estimated that it won't take long for us to pass the FDA approval." David said confidently, "I have started a public relations action against the FDA."
What he said about the public relations action will be clear to everyone, providing all kinds of comfortable enjoyment for the professionals responsible for FDA review, promoting their academic works, holding special academic conferences for them, etc. These large pharmaceutical companies With rich operating experience, those reviewers can be convinced.
This is also one of the reasons why small pharmaceutical companies cannot afford FDA review costs. Not only does a large amount of money need to be spent on clinical trials for the launch of new drugs, but public relations costs are also not a small number; and the most important thing is that those reviewers are very serious about large pharmaceutical companies. Understand, they can accept their kindness with confidence, but have never dealt with small pharmaceutical companies, and sometimes they want to show good people are not necessarily dare to accept.
In addition, large pharmaceutical companies can quickly pass their new drugs through various public relations activities. Then consider the issue from another perspective. They can also use public relations activities to prevent certain new drugs that may impact themselves from being approved. In order to protect themselves Their interests, they can definitely do it.
"Excellent, I believe shareholders will be very happy to hear this news!" Steve said excitedly, as an executive, they can also get high bonuses from it.
"I'm sorry, gentlemen, I'm afraid I'm going to interrupt your celebration. There is bad news here!" Steve and David are very happy, but the other executive is looking grim.
"Norman, what's wrong? Is there something wrong with the development? Or is there another company's development plan that crashed with us? But I haven't received similar news." David asked doubtfully.
"I just received an email, and this email tells me the unfortunate news that there is already a cheap macular degeneration treatment drug on the market, and the price of this drug is only for our plan to Lan. One-fifth of nilimumab's pricing, that is to say, ranibizumab will face the impact of cheap drugs before it has been approved. "Norman said seriously," This is just too bad. "
Pharmaceutical companies can't hear the word cheap. What we do is to save human life and maintain human health, a sacred and great cause. Can human life and health be measured by money? People who sell cheap drugs simply do not respect human life and health!
"What kind of medicine? Why didn't I receive the news?" David and Steve looked at each other. If a company developed similar products, how could they not know?
"It is not a drug specifically for macular degeneration, but a labelled external medicine. Some doctors have found that Roche's Avastin has a significant effect on macular degeneration, so it is often prescribed to patients with macular degeneration by way of external labeling. There is a tendency to spread in this way, and we have not noticed these before. "Norman showed them the content of the printed email." Look, the rising curve is very obvious, which will definitely have a huge impact on our Ranibizumab. . "
"Damn! These doctors are too irresponsible, and the external use of the label does not guarantee the safety of the patient." David is filled with indignation. How can you use the method of use that is not marked on the label? Don't these doctors know that this will affect our earnings? Did we spend the money on the doctor in vain? They don't talk about professional ethics too!
"It seems that we must immediately convene an emergency meeting and find a way to solve this problem!" The executives took the opportunity to make a decisive decision and immediately called other people to convene an emergency meeting.
Norman showed them the emails they received on the big screen, "Now we need to prohibit these doctors from continuing to use off-label medicines to prescribe this medicine to patients with macular degeneration, and also convince Roche not to treat it Macular degeneration is added to Avastin's label, let's talk about it, what is the way? "
"We can ask the academic community to issue a special paper to analyze the comparison of the efficacy of Avastin and Ranibizumab, and let them tell those patients that there are hidden safety risks in using Avastin to treat macular degeneration." Someone immediately suggested that As for whether there is such a difference between these two drugs, they do not care.
Nova Corporation spends a lot of money every year to provide sponsorship to academia. They will find scholars who are willing to do these studies and can make satisfactory research results. They have no doubt about this.
"I believe that Roche is not willing to sell macular degeneration treatment drugs at such a cheap price." Both are pharmaceutical giants, and their ideas about each other can't be more clear. "We can give up some markets and let Roche help us sell ranibizumab. In exchange for their prohibition of Avastin for the treatment of macular degeneration. "
"In this case, we have to raise the price, otherwise the profit from Ranibizumab will not satisfy shareholders." Steve said.
"Roche will support the price increase ~ EbookFREE.me ~ Isn't that what they did on Vitamin C?" Norman shrugged, and they were familiar with the price union.
"We also need to conduct public relations with the FDA to prevent doctors from prescribing drugs to patients with macular degeneration in the form of off-label drugs. Of course, this should be placed after the publication of related papers." David suggested that FDA should also take into account the impact, flat Prohibition for no reason is a bit excessive, but if there are several papers that point out the safety risks of Avastin, it will be different.
"Okay, let's do that, and now start to assign tasks, David, you are responsible for the FDA's public relations, Steve, you go to find relevant scholars; let them come up with papers as soon as possible and publish them in the" New England Journal of Medicine " In a journal above this level; I will talk to the people of Roche, let ’s listen to their conditions first! "After some discussion, Norman finished the assignment, and packed up and was ready to disband.
"Wait, there is one more thing. The Chinese branch wants us to help them put pressure on the local government to stop the listing of a local drug." Someone said quickly.
"Ranibizumab is now the most important thing, let them do it themselves!"
In reality, this incident did not happen at this time, but it was very representative, so I changed it to the present.